Latest News

InflaRX raises US$55m in Series D round

InflaRX lead candidate (blue) binding complement factor C% (red). © InflaRx


by tg

German infection specialist InflaRx (Jena) raised US$55m in a Series D financing co-led by Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC  to finance its clinical programmes with its lead asset IFX-1.

According to the company, the transaction consists of a US$30m capital increase and a US$25m secondary share purchase. Proceeds from the capital increase will be used to advance Phase IIb development of InflaRx's lead IFX-1, a first-in-class anti-human complement factor C5a monoclonal antibody, in chronic inflammatory and auto-immune indications and to advance non disclosed preclinical development of pipeline products.

In July 2017, InflaRx published results from a Phase IIa open label trial in patients suffering from the autoimmune skin disease Hidradenitis Suppurativa, which demonstrated the disease modifying activity of IFX-1. After having turned away from clinical testing of the compound in the investor-averse field of sepsis, for which no approved treatment exists, InflaRx has built a robust pipeline in different inflammatory/autoimmune indications.

Cellestia: €20m to get to Phase II

Funds will be used to finance the operations and to advance the ongoing Phase l clinical trial for the company’s programme CB-103 into Phase II....

AMR: ENABLE selects Mutabilis candidate

Efficacy of beta-lactam antibiotics, which represent 65% of the antibiotics sold throughout the world, is increasingly challenged in Gram-negative...

Merry Christmas and a Happy New Year

Incyte licenses Morphosys’ tafasitamab in US$2bn deal

Tafasitamab (MOR208, Xmab5574) is an Fc-engineered antibody originally developed at Xencor, Inc. that targets CD19. The antibody is in clinical...

Microbiota contribute to skin damage in cancer therapy

EGFR inhibitors such as erlotinib interrupt the growth of cancer cells and are approved to treat malignancies such as lung and colorectal cancer....

Merck and 4SC collaborate in immunooncology

Under the agreement, 4SC AG will sponsor clinical testing of a combination of its oral class I histone deacetylase (HDAC) blocker domatinostat (HDAC...

Sanofi buys Synthorx Inc for US$2.35bn

Sanofi SA‘s and Synthorx Inc's Boards approved the deal which forsees that Sanofi will acquire all of the outstanding shares of Synthorx for $68 per...